Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: Cohort study of 1,326,312 patients in France

British Journal of DermatologyPenso L, Dray-Spira R, Weill A, et al. | January 10, 2022


In patients with psoriasis, systemic treatments (including biologics) were not linked with an elevated risk of in-hospital mortality due to COVID-19. Maintaining systemic treatment for psoriasis during the pandemic is supported by the findings.

  • This study included 1,326,312 patients with psoriasis (mean age 59 years; males, 48%) who were registered in the French national health-insurance (Système National des Données de Santé, SNDS) database between 2008 and 2019.

  • Patients were grouped based on their baseline treatment: biologics, nonbiologics, topicals or no treatment.

  • Propensity score-weighted Cox models demonstrated that risk of hospitalization for COVID-19 was linked with exposure to topicals or nonbiologics [hazard ratio: 1·11 and 1·27, respectively] during 15 February to 30 June 2020, and with all exposure types, during 1 October 2020 to 31 January 2021.

  • None of the exposure types was found to be related to in-hospital mortality due to COVID-19.

Read the full article on British Journal of Dermatology